Sorrento Therapeutics, Inc.
(NASDAQ : SRNE)

( )
SRNE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 1.88%70.300.0%$1825.85m
GILDGilead Sciences, Inc. 1.61%74.521.0%$1331.13m
NVAXNovavax, Inc. 18.83%54.79102.0%$666.80m
AMGNAmgen, Inc. 1.48%229.791.3%$664.07m
REGNRegeneron Pharmaceuticals, Inc. 1.59%569.912.5%$571.28m
VRTXVertex Pharmaceuticals, Inc. 1.77%290.001.9%$539.44m
BIIBBiogen, Inc. 0.02%304.531.6%$421.31m
ILMNIllumina, Inc. 1.51%354.703.5%$346.79m
SRNESorrento Therapeutics, Inc. 5.33%5.341.8%$311.20m
SGENSeattle Genetics, Inc. 1.02%155.776.1%$235.46m
ALXNAlexion Pharmaceuticals, Inc. 0.36%101.502.0%$221.68m
CODXCo-Diagnostics, Inc. 0.81%18.700.0%$199.81m
MGNXMacroGenics, Inc. 0.84%25.376.2%$199.40m
AAgilent Technologies, Inc. 5.24%84.981.6%$189.94m
INCYIncyte Corp. 1.79%101.152.5%$150.25m

Company Profile

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.